Dual–target platinum(IV) complexes reverse cisplatin resistance in triple negative breast via inhibiting poly(ADP–ribose) polymerase (PARP–1) and enhancing DNA damage

Insights into Mechanisms and Promising Triple Negative Breast Cancer Therapeutic Potential for a Water-Soluble Ruthenium Compound

“…Metallodrugs have shown preclinical efficacy in TNBC mouse models, but less than a dozen studies have focused on the mechanistic action of these compounds. , In order to translate the potential of these highly efficacious drugs for clinical use, the underlying processes involved in their mode of action must be detailed. The studies described here provide insight into a potential mode of action for Ru-IM in TNBC.…”

Novel NF-κB Inhibitor-Conjugated Pt(IV) Prodrug to Enable Cancer Therapy through ROS/ER Stress and Mitochondrial Dysfunction and Overcome Multidrug Resistance

“…(OC-6-33)-Diamminetrichlorido((E)-4- (2-(2-methoxy-5-(3-oxo-3-(3,4,5-trimethoxyphenyl)prop-1-en-1-yl)phenoxy)ethoxy)-4-oxobutanoicate)-platinum (8). Yellow solid; yield, 43.6%.…”

“…Platinum(II) drugs, such as cisplatin (CDDP), as DNA damage anticancer drugs (Figure ), are considered first-line chemotherapy agents and are usually employed for treating various solid tumors. − It is universally accepted that DNA-damage-causing platinum(II)-based agents have led to great progress against most solid cancers during the last few decades because of their low price, good curative effects, and broad applicability. − However, these DNA-damaging platinum(II)-based antitumor agents are restricted by their poor selectivity and some serious side effects (e.g., nephrotoxicity, ototoxicity, and myelosuppression) in addition to poor stability. − More unfortunately, in addition to the above shortcomings, the inherent or acquired drug resistance further limits their use in the clinic. , Therefore, it is important for researchers to pay close attention to the development of next-generation platinum-based antitumor agents to improve the antitumor efficiency, decrease defects, and reverse drug resistance.…”

Glycyrrhetinic Acid as a Hepatocyte Targeting Ligand-Functionalized Platinum(IV) Complexes for Hepatocellular Carcinoma Therapy and Overcoming Multidrug Resistance

“…More importantly, the two axial ligands introduced in platinum(IV) complexes could be used to promote tumor-targeting ability or bioavailability and enhance cellular uptake, respectively. , Therefore, multifunctional platinum(IV) complexes are an effective strategy to enhance antitumor efficacy, overcome the drug resistance, and reduce the side effects of the conventional platinum(II)-based drugs because of the different mechanism of antitumor action. For example, multifunctional platinum(IV) complexes (Figure ), such as CX-4945-platinum(IV), chalcone-platinum(IV), , chlorambucil-platinum(IV), BBI-608-platinum(IV), pterostilbene-platinum(IV), evodiamine-platinum(IV), fenofibric acid-platinum(IV), ketoprofen-platinum(IV), PARPis-platinum(IV), and so on, not only displayed stronger antitumor activity than that of cisplatin both in vitro and in vivo but also exhibited low toxicity toward normal tissue in cisplatin-sensitive or -resistant tumor xenograft models. Therefore, exploring a multifunctional platinum(IV) prodrug with liver-targeting ability is an ideal strategy for the development of potential anti-HCC drugs.…”